Texting your way to better glaucoma care: new trial tests daily reminders
NCT ID NCT07480577
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether daily SMS or WhatsApp reminders can help people with primary open-angle glaucoma stick to their eye-drop schedule. About 84 adults will be split into two groups: one gets the reminders plus weekly educational messages for 3 months, the other gets standard care. The goal is to see if the reminders improve medication adherence and lower eye pressure, which could slow vision loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
digital reminder system (SMS/WhatsApp messages)
What this could lead to
If it works, this could offer a simple, low-cost way to help glaucoma patients stick to their eye-drop routine and better control eye pressure.
What could go wrong
This is a small, early-stage trial with only 84 people over 3 months. The reminders may not improve adherence or eye pressure in the long run, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY OPEN ANGLE GLAUCOMA (POAG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.